GO:0042267 natural killer cell mediated cytotoxicity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042267 describes the directed killing of a target cell by a natural killer (NK) cell through release of cytotoxic granules or engagement of death receptors.
• NK cells kill via two major routes: granule exocytosis (perforin and granzymes) and death receptor ligation such as FasL/Fas and TRAIL/TRAIL-R.
• NK cell activation is governed by a balance of germline-encoded activating and inhibitory receptors, including NKG2D, NKp30, NKp44, NKp46, KIRs, and NKG2A.
• Antibody-dependent cellular cytotoxicity (ADCC) through CD16 (FcγRIIIa) is a clinically important NK killing mechanism exploited by therapeutic antibodies.
• Tumor cells evade NK cytotoxicity through multiple mechanisms, including loss of ligands, shedding of soluble NKG2D ligands, and altered intracellular trafficking such as CHMP2A-mediated resistance.
• CRISPR knockout, knock-in, point-mutation, and overexpression models enable causal dissection of NK receptor-ligand axes and cytotoxicity regulators.
Description
Natural killer (NK) cells are innate lymphoid cells that provide rapid, antigen-independent surveillance against infected and transformed cells. The Gene Ontology biological process GO:0042267, natural killer cell mediated cytotoxicity, captures the directed killing of a target cell by an NK cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors. This process is central to antiviral defense, tumor immunosurveillance, and the mechanism of action of several therapeutic antibodies. Understanding GO:0042267 at molecular resolution requires defining the receptor-ligand interactions that trigger NK activation, the intracellular signaling that licenses degranulation, and the effector molecules that execute target cell death. Because NK cytotoxicity is modulated by both activating and inhibitory inputs, it is a paradigm for studying how immune cells integrate positive and negative signals to reach a kill decision. In cancer, NK cells can eliminate malignant cells, but tumors frequently acquire resistance through ligand loss, shedding, or altered intracellular trafficking. In infectious disease, NK cytotoxicity contributes to control of pathogens such as SARS-CoV-2 and Plasmodium falciparum, and can be harnessed through antibody-dependent mechanisms. Consequently, GO:0042267 is a high-value term for immunology, immuno-oncology, and therapeutic antibody research, and it is increasingly studied with CRISPR-based functional genomics.
natural killer cell mediated cytotoxicity At A Glance
| GO ID | GO:0042267 |
|---|---|
| GO term | natural killer cell mediated cytotoxicity |
| Ontology | biological_process |
| Definition | The directed killing of a target cell by a natural killer cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors. |
| Synonyms | killer activity; natural killer cell mediated cell death; natural killer cell mediated cell killing; natural killer cell mediated cytolysis; NK cell mediated cytotoxicity |
| Major function | Direct elimination of infected or transformed target cells by NK cells via granule exocytosis or death receptor engagement |
| Key effector molecules | Perforin, granzymes, FasL, TRAIL, and CD16-mediated ADCC |
| Key receptors | NKG2D, NKp30, NKp44, NKp46, KIRs, NKG2A, and CD16 |
| Disease relevance | Cancer immunosurveillance, viral infection, and antibody-based immunotherapy |
What Is GO:0042267?
GO:0042267 (natural killer cell mediated cytotoxicity) is the biological process in which a natural killer cell directly kills a target cell. According to the QuickGO definition, this killing occurs either through the release of granules containing cytotoxic mediators or through the engagement of death receptors. The term encompasses the full effector program of NK cells, from target recognition and immune synapse formation to granule polarization, exocytosis of perforin and granzymes, and receptor-mediated apoptosis of the target. It is synonymous with NK cell mediated cell death, NK cell mediated cell killing, NK cell mediated cytolysis, and killer activity. The process is distinct from T-cell-mediated cytotoxicity and from other forms of cell death because it is executed by NK cells and does not require prior antigen-specific sensitization.
Why Is natural killer cell mediated cytotoxicity Important in Cell Biology?
GO:0042267 is important because NK cell-mediated cytotoxicity is a first-line defense against viral infection and malignant transformation, and it is the effector mechanism of several approved and investigational therapeutic antibodies. Unlike T cells, NK cells do not require antigen-specific priming, so they can kill target cells rapidly and broadly. This makes NK cytotoxicity a critical component of innate immunity and a major focus for cancer immunotherapy, where enhancing NK killing or overcoming tumor resistance can improve patient outcomes. The process is also relevant to infectious disease, including SARS-CoV-2 and malaria, where antibody-dependent NK cytotoxicity contributes to pathogen control. Because NK killing is controlled by a complex balance of activating and inhibitory receptors, it provides a tractable system for studying signal integration and for developing CRISPR-based models of immune dysfunction.
• Provides rapid, antigen-independent killing of virus-infected cells and tumor cells.
• Underlies the mechanism of action of therapeutic antibodies that engage CD16-mediated ADCC.
• Is a key component of cancer immunosurveillance and a determinant of tumor immunoediting.
• Contributes to control of SARS-CoV-2 through antibody-dependent NK cytotoxicity, which can be restrained by Siglec-9.
• Participates in antibody-dependent killing of Plasmodium falciparum-infected red blood cells.
• Is modulated by tumor-derived factors such as dipeptidase 1 interacting with NKp30 on NK cells.
• Can be limited by tumor-intrinsic regulators such as CHMP2A that affect sensitivity to NK cytotoxicity.
• Is governed by germline-encoded activating and inhibitory receptors, making it a model for signal integration.
• Offers multiple CRISPR-tractable nodes for functional genomics and drug target discovery.
• Is relevant to immunotherapy design, including NK cell engagers and CAR-NK approaches.
What Happens During natural killer cell mediated cytotoxicity?
Target cell recognition and immune synapse formation
In simple terms: The NK cell first touches the target cell and decides whether it is dangerous.
NK cell cytotoxicity begins with contact between the NK cell and a potential target cell, leading to formation of an immune synapse. During this step, NK cells survey target cells for surface ligands of activating receptors such as NKG2D, NKp30, NKp44, and NKp46, while simultaneously checking inhibitory receptors such as KIRs and NKG2A that recognize MHC class I. The balance of activating and inhibitory signals determines whether the NK cell becomes licensed to kill. This recognition phase is antigen-independent and does not require prior sensitization, distinguishing NK cells from T cells.
Activating and inhibitory receptor signaling
In simple terms: Positive and negative signals inside the NK cell are weighed to make a kill decision.
Engagement of activating receptors triggers intracellular signaling through adaptor molecules and kinases that promote actin reorganization, calcium flux, and transcriptional programs required for cytotoxicity. Inhibitory receptors deliver dominant negative signals that prevent killing when target cells display sufficient MHC class I. The integration of these signals ensures that healthy cells are spared while infected or transformed cells are eliminated. Dysregulation of this balance can lead to impaired NK cytotoxicity or, conversely, inappropriate killing.
Granule polarization and exocytosis
In simple terms: The NK cell moves its toxic granules to the contact point and releases them.
Upon activation, the microtubule organizing center and cytotoxic granules polarize toward the immune synapse. Granules containing perforin and granzymes fuse with the plasma membrane and release their contents into the synaptic cleft. Perforin forms pores in the target cell membrane, allowing granzymes to enter and initiate apoptosis. This granule exocytosis pathway is a hallmark of NK cell-mediated cytotoxicity and is tightly regulated to avoid bystander damage.
Death receptor-mediated killing
In simple terms: The NK cell can also kill by flipping death switches on the target cell.
In addition to granule exocytosis, NK cells can express death ligands such as FasL and TRAIL that engage death receptors on target cells. Ligation of Fas or TRAIL receptors triggers caspase activation and apoptosis in the target cell. This pathway provides an alternative or complementary killing mechanism, particularly when granule-mediated killing is impaired. Death receptor-mediated cytotoxicity is important for eliminating certain tumor cells and infected cells.
Antibody-dependent cellular cytotoxicity (ADCC)
In simple terms: Antibodies can tag target cells so NK cells recognize and kill them more efficiently.
NK cells express CD16 (FcγRIIIa), which binds the Fc portion of IgG antibodies coating target cells. This engagement activates NK cells and triggers ADCC, a major mechanism of action for therapeutic antibodies. ADCC has been demonstrated against SARS-CoV-2 and Plasmodium falciparum-infected red blood cells, and can be modulated by inhibitory receptors such as Siglec-9. ADCC is a clinically important route of NK cytotoxicity and a focus of immunotherapy development.
Target cell apoptosis and resolution
In simple terms: The target cell dies, and the NK cell can move on to kill again.
Following delivery of cytotoxic mediators, the target cell undergoes apoptosis characterized by caspase activation, DNA fragmentation, and membrane blebbing. NK cells can detach and sequentially kill multiple targets, a process sometimes called serial killing. Tumor cells can acquire resistance to this process through mechanisms such as CHMP2A-mediated changes in sensitivity to NK cytotoxicity. Understanding the resolution phase is important for designing strategies to overcome resistance.
Key Genes Involved in GO:0042267 natural killer cell mediated cytotoxicity
The following genes and proteins are central to natural killer cell mediated cytotoxicity (GO:0042267), spanning recognition, signaling, effector function, and regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRF1 | Perforin pore formation in target cell membrane | Loss-of-function causes familial hemophagocytic lymphohistiocytosis; key effector of granule exocytosis |
| GZMB | Granzyme B serine protease that activates caspases | Major cytotoxic mediator; target for functional studies of granule-mediated killing |
| FASLG | Fas ligand that engages Fas on target cells | Death receptor pathway of NK cytotoxicity |
| TNFSF10 | TRAIL that engages TRAIL receptors | Alternative death receptor-mediated killing |
| FCGR3A | CD16 FcγRIIIa receptor for IgG Fc | Mediates ADCC; target for therapeutic antibody engineering |
| KLRK1 | NKG2D activating receptor | Recognizes stress-induced ligands on tumor and infected cells |
| NCR3 | NKp30 activating receptor | Interacts with tumor ligands such as dipeptidase 1 to modulate cytotoxicity |
| NCR2 | NKp44 activating receptor | Contributes to NK activation and cytotoxicity |
| NCR1 | NKp46 activating receptor | Key NK-specific activating receptor |
| KIR2DL1 | Inhibitory receptor for HLA-C | Controls NK licensing and tolerance |
| KLRC1 | NKG2A inhibitory receptor | Recognizes HLA-E and restrains NK activation |
| SIGLEC9 | Inhibitory sialic acid-binding receptor | Restrains antibody-dependent NK cytotoxicity against SARS-CoV-2 |
| CHMP2A | ESCRT-III component regulating membrane trafficking | Tumor-intrinsic regulator of sensitivity to NK cytotoxicity |
| DPEP1 | Dipeptidase 1 expressed by colon cancer cells | Interacts with NKp30 to attenuate NK cytotoxicity |
| HCST | Adaptor for NKG2D signaling | Required for NKG2D-mediated activation |
| TYROBP | Adaptor for activating NK receptors | Transduces signals from NKp30, NKp44, NKp46, and NKG2D |
| SH2D1B | SAP-family adaptor in NK signaling | Modulates activating receptor signaling |
How Is natural killer cell mediated cytotoxicity Regulated?
NK cell-mediated cytotoxicity is regulated at multiple levels. Receptor-ligand interactions provide the primary checkpoint, with inhibitory receptors such as KIRs and NKG2A overriding activating signals when MHC class I is present. Cytokine stimulation, including IL-2, IL-15, and IL-12, can prime NK cells for enhanced cytotoxicity. Tumor-derived factors can suppress NK function; for example, dipeptidase 1 from colon cancer cells interacts with NKp30 to attenuate NK cytotoxicity. Intracellular trafficking regulators such as CHMP2A can alter tumor cell sensitivity to NK-mediated killing. Inhibitory receptors such as Siglec-9 can restrain antibody-dependent NK cytotoxicity, providing a target for checkpoint blockade. Together, these layers of regulation ensure that NK killing is tightly controlled and responsive to context.
natural killer cell mediated cytotoxicity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRF1 | Familial hemophagocytic lymphohistiocytosis; impaired granule-mediated killing | PRF1 knockout NK cell line or primary NK cells |
| FCGR3A | Antibody therapy response; ADCC efficacy | FCGR3A knock-in reporter or point-mutant NK cells |
| SIGLEC9 | SARS-CoV-2 antibody-dependent NK cytotoxicity | SIGLEC9 knockout NK cells for ADCC assays |
| CHMP2A | Tumor resistance to NK cytotoxicity | CHMP2A knockout tumor cells for NK co-culture |
| DPEP1 | Colon cancer immune evasion via NKp30 | DPEP1 knockout colon cancer cells for NK cytotoxicity assays |
Cancer immunosurveillance and immunotherapy
NK cells contribute to cancer immunosurveillance by recognizing and killing transformed cells. Tumors can evade NK cytotoxicity through multiple mechanisms, including shedding of NKG2D ligands, downregulation of activating ligands, and upregulation of inhibitory signals. CHMP2A has been identified as a tumor-intrinsic regulator of sensitivity to NK cell-mediated cytotoxicity, suggesting that targeting trafficking pathways could enhance NK killing. Therapeutic antibodies that engage CD16-mediated ADCC rely on NK cytotoxicity for efficacy, making this process a central focus of immuno-oncology.
Viral infection and antibody-dependent killing
NK cells are critical for early control of viral infections through direct cytotoxicity and cytokine production. In SARS-CoV-2 infection, antibody-dependent NK cytotoxicity can be restrained by Siglec-9, highlighting a checkpoint that may limit antiviral efficacy. Understanding how NK cytotoxicity is regulated during viral infection can inform vaccine and therapeutic antibody design.
Parasitic infection
NK cell antibody-dependent cellular cytotoxicity has been studied against Plasmodium falciparum-infected red blood cells, suggesting a role in controlling malaria. This demonstrates that GO:0042267 extends beyond viral and tumor targets to parasitic pathogens.
Immune dysregulation and primary immunodeficiencies
Defects in granule exocytosis machinery, such as perforin deficiency, cause severe immune dysregulation including familial hemophagocytic lymphohistiocytosis. These disorders underscore the importance of tightly regulated NK cytotoxicity for immune homeostasis.
From natural killer cell mediated cytotoxicity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate NK cytotoxicity? | CRISPR knockout in NK cell line or primary NK cells followed by co-culture killing assays |
| Does a point mutation in a receptor alter ligand binding? | CRISPR point-mutation knock-in of the receptor in NK cells |
| Can a therapeutic antibody enhance ADCC? | CD16 (FCGR3A) knock-in reporter NK cells and antibody-dependent cytotoxicity assays |
| Does a tumor gene confer resistance to NK killing? | CRISPR knockout of the candidate gene in tumor cells followed by NK co-culture |
| Can a tagged receptor be tracked during immune synapse formation? | Tagged knock-in of the receptor in NK cells and imaging |
| Does overexpression of an inhibitory ligand suppress NK killing? | Overexpression of the ligand in target cells and NK cytotoxicity assays |
How to Study the natural killer cell mediated cytotoxicity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Chromium-51 release assay | Target cell lysis | Quantifying NK cytotoxicity |
| Flow cytometry-based killing assay | Percentage of dead target cells | High-throughput NK cytotoxicity screening |
| ADCC assay | Antibody-dependent NK killing | Therapeutic antibody evaluation |
| Live-cell imaging | Immune synapse dynamics and granule polarization | Mechanistic studies of NK killing |
| RNA sequencing | Transcriptional changes in NK cells or targets | Identifying regulators of cytotoxicity |
| Mass spectrometry | Protein composition of immune synapse | Discovering new effector molecules |
| CRISPR knockout screen | Genes required for or limiting cytotoxicity | Functional genomics of NK resistance |
Cytotoxicity assays
Standard chromium-51 release or flow cytometry-based killing assays measure the ability of NK cells to lyse target cells. These assays are used to quantify NK cytotoxicity and to test the effect of genetic perturbations. Antibody-dependent cellular cytotoxicity can be measured by adding target-specific antibodies to the co-culture.
Imaging and immune synapse analysis
Live-cell imaging and confocal microscopy can visualize immune synapse formation, granule polarization, and exocytosis. These methods reveal the spatial and temporal dynamics of NK-target interactions. Tagged knock-in of effector proteins enables tracking of granule movement.
Transcriptomics and proteomics
RNA sequencing and mass spectrometry can identify genes and proteins that change upon NK activation or target engagement. These approaches help define the molecular signature of cytotoxic NK cells. Proteomic analysis of immune synapses can reveal new regulators of cytotoxicity.
CRISPR functional genomics
Genome-wide CRISPR knockout screens in NK cells or target cells can identify genes that regulate cytotoxicity. These screens have uncovered tumor-intrinsic regulators such as CHMP2A and ligand-receptor interactions such as DPEP1-NKp30. Follow-up validation with individual knockouts confirms causality.
How CRISPR Can Be Used to Study GO:0042267 natural killer cell mediated cytotoxicity
Knockout
CRISPR knockout is used to delete candidate genes in NK cells or target cells to test their requirement for cytotoxicity. For example, knockout of CHMP2A in tumor cells increases sensitivity to NK-mediated killing. Knockout of DPEP1 in colon cancer cells can modulate NKp30-dependent cytotoxicity. These models provide causal evidence for gene function in GO:0042267.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in receptors or effector proteins to dissect domain functions. For instance, point mutations in CD16 can alter Fc binding and ADCC. Point mutations in NKG2D or NKp30 can reveal ligand-binding residues required for activation. These models are valuable for structure-function studies of NK cytotoxicity.
Knock-in
Knock-in of reporter genes or tags allows tracking of NK receptors and effector molecules in live cells. Tagged knock-in of perforin or granzymes enables visualization of granule trafficking. Knock-in of human CD16 into mouse NK cells can humanize ADCC models. These approaches facilitate precise mechanistic studies.
Overexpression
Overexpression of activating ligands or inhibitory molecules in target cells can test their impact on NK cytotoxicity. Overexpression of NKG2D ligands can enhance NK killing, while overexpression of inhibitory ligands can suppress it. Overexpression of CHMP2A or DPEP1 can model tumor resistance. These models complement loss-of-function studies.
How EDITGENE Supports natural killer cell mediated cytotoxicity Research
Researchers studying natural killer cell mediated cytotoxicity-related genes often need to determine whether a candidate gene is causally involved in NK killing, whether a specific mutation alters receptor function, or whether a tumor gene confers resistance. EDITGENE provides end-to-end CRISPR services to build precisely engineered cell models for these questions, from knockout and point mutation to knock-in, overexpression, and library screening.
Contact EDITGENE today to design your custom CRISPR model for natural killer cell mediated cytotoxicity research.
Frequently Asked Questions About natural killer cell mediated cytotoxicity
What is natural killer cell mediated cytotoxicity (GO:0042267)?
It is the biological process in which a natural killer cell directly kills a target cell through the release of cytotoxic granules or engagement of death receptors.
What genes are involved in natural killer cell mediated cytotoxicity?
Key genes include PRF1, GZMB, FASLG, TNFSF10, FCGR3A, KLRK1, NCR1, NCR2, NCR3, KIR2DL1, KLRC1, SIGLEC9, CHMP2A, and DPEP1.
How do NK cells kill target cells?
NK cells kill via granule exocytosis of perforin and granzymes, death receptor ligation such as FasL/Fas and TRAIL, and antibody-dependent cellular cytotoxicity through CD16.
What is the role of NK cells in cancer?
NK cells provide immunosurveillance by recognizing and killing transformed cells, but tumors can evade through ligand loss, shedding, or resistance mechanisms such as CHMP2A.
What is antibody-dependent cellular cytotoxicity (ADCC)?
ADCC is a mechanism in which antibodies coat target cells and engage CD16 on NK cells to trigger killing, and it is a major mode of action of therapeutic antibodies.
How is NK cytotoxicity regulated?
It is regulated by the balance of activating and inhibitory receptors, cytokines, tumor-derived factors, and intracellular trafficking regulators such as CHMP2A.
Which receptors activate NK cells?
Activating receptors include NKG2D, NKp30, NKp44, and NKp46, which signal through adaptors such as TYROBP and HCST.
Which receptors inhibit NK cells?
Inhibitory receptors include KIRs, NKG2A, and Siglec-9, which restrain NK activation and cytotoxicity.
How can CRISPR be used to study NK cytotoxicity?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of genes in NK cells or target cells, and library screens can identify new regulators.
What diseases are linked to NK cell mediated cytotoxicity?
It is linked to cancer, viral infections such as SARS-CoV-2, parasitic infections such as malaria, and immune dysregulation disorders such as familial hemophagocytic lymphohistiocytosis.
Conclusion
GO:0042267 natural killer cell mediated cytotoxicity is a central biological process in innate immunity, encompassing granule exocytosis, death receptor engagement, and antibody-dependent killing. Its molecular dissection has revealed a complex balance of activating and inhibitory receptors, effector molecules, and tumor-intrinsic resistance factors. Because NK cytotoxicity is critical for cancer immunosurveillance and antiviral defense, it is a high-priority target for immunotherapy and functional genomics. CRISPR-based models provide powerful tools to test causality and to discover new therapeutic nodes within this pathway.
References
- 1. Prager I et al.. 2019. Mechanisms of natural killer cell-mediated cellular cytotoxicity.. J Leukoc Biol 105(6):1319-1329 PMID: 31107565
- 2. Chin DS et al.. 2022. Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy.. Curr Pharm Biotechnol 23(4):552-578 PMID: 34414871
- 3. Saini P et al.. 2023. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.. mBio 14(1):e0339322 PMID: 36728420
- 4. Chen Y et al.. 2020. Research Progress on NK Cell Receptors and Their Signaling Pathways.. Mediators Inflamm 2020:6437057 PMID: 32774149
- 5. Malmberg KJ et al.. 2017. Natural killer cell-mediated immunosurveillance of human cancer.. Semin Immunol 31:20-29 PMID: 28888619
- 6. Dick JK et al.. 2022. Natural Killer Cell Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity Against Plasmodium falciparum-Infected Red Blood Cells.. Methods Mol Biol 2470:641-657 PMID: 35881380
- 7. Kim JT et al.. 2025. Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells.. Sci Rep 15(1):34777 PMID: 41053108
- 8. Bernareggi D et al.. 2022. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.. Nat Commun 13(1):1899 PMID: 35393416
